• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 18, 2019

View Archived Issues

Combinations locked? Bid for new pairings via Pfizer propels $11.4B Array grab

Pfizer Inc. wasn't shy about talking specifics with regard to synergy in its merger with Array Biopharma Inc., for which the pharma giant has agreed to pay $48 per share in cash – a 62% premium to Friday's closing price of $29.59 – in a deal with an enterprise value of about $11.4 billion. The boards of both companies have approved the merger, expected to finish in the second half of this year. Read More

Challenging university patents just got a whole lot easier

Stepping through a door it opened last year, the U.S. Court of Appeals for the Federal Circuit ruled Friday that states do not enjoy sovereign immunity from inter partes review (IPR). Read More

Amid the turmoil, Hansoh lands $1B IPO on Hong Kong Exchange

HONG KONG – China-based Hansoh Pharmaceutical Group Co. Ltd. had a strong debut on Hong Kong's stock market and raised $1 billion on Friday – despite widespread protests and a political crisis here – becoming the biggest health care IPO in Hong Kong this year. Read More

VBI's unmet phase III secondary endpoint leaves stock unprotected on hep B results

While VBI Vaccines Inc.'s Protect phase III top-line data showed the hepatitis B drug Sci-B-Vac met its co-primary endpoints, failure to meet a secondary endpoint sunk the company stock by 65.6% on Monday. Read More

New name, new funding for Probiodrug in fight against Alzheimer's

LONDON – Probiodrug AG announced it is changing its name to Vivoryon Therapeutics AG, as it gears up to start a European and U.S. phase IIb program of PQ-912 in the treatment of Alzheimer's disease, after securing grant and equity funding for the trials. Read More

Half-used medicine cabinet means half-full glass for CLL

AMSTERDAM – Since 2014, approvals and expanding indications for Bruton's tyrosine kinase (BTK) inhibitors Imbruvica (ibrutinib, Pharmacyclics LLC/Janssen Biotech Inc.) and Calquence (acalabrutinib, Astrazeneca plc), and Bcl-2 inhibitor Venclexta (venetoclax, Abbvie Inc./Roche AG) have given many chronic lymphocytic leukemia (CLL) patients chemotherapy-free treatment options. Many cancer patients dread chemotherapy almost as much as they dread their cancer, and frail patients may be unable to withstand the toxicities of chemotherapy and greatly prefer those chemotherapy-free regimens. Read More

Eyeing personalized Rx, Harvard, UCSF uncover L-dopa microbial metabolism

There is wide variability of individual responses to a specific prescription drug. That can have some genetic basis inherent to a particular individual, but the microbiome also has been suspected to play a part. Read More

UCSF researchers use metagenomic NGS to ID mystery pathogens

Diagnosing serious infections in the hospital is often a process of elimination. A series of tests for individual suspected pathogens are used one at a time, sometimes while treatment is already in progress without a definitive diagnosis. But the cause of roughly half of serious infections, such as meningitis, encephalitis, pneumonia and sepsis, remain undiagnosed via such a process. Read More

Financings

Prometic Life Sciences Inc., of Laval, Quebec, said it completed its equity rights offering, raising CA$37.99 million (US$28.35 million). The company will use the proceeds to finance ongoing operations, which include the plasma-derived therapeutics segment, small-molecule therapeutics segment and corporate functions. Read More

Other news to note

Beigene Ltd., of Beijing, signed an agreement with Celgene Corp., of Summit, N.J., to terminate the parties' global collaboration for tislelizumab, Beigene's investigational anti-PD-1 antibody, in advance of the pending acquisition of Celgene by Bristol-Myers Squibb Co., of New York. In connection with the termination, Celgene has agreed to pay $150 million to Beigene.  Read More

Regulatory front

Merck & Co. Inc., Eli Lilly and Co., and Amgen Inc., along with the Association of National Advertisers Inc., filed suit against the U.S. Department of Health and Human Services (HHS) to stop a rule requiring TV ads for most prescription drugs to include the wholesale acquisition cost (WAC) of the drug.  Read More

Regulatory actions for June 17, 2019

Read More

Conference data: European Hematology Association (Amsterdam)

Read More

Clinical data for June 17, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe